表紙:子宮頸癌診断検査の世界市場:医療機器のパイプライン評価
市場調査レポート
商品コード
366601

子宮頸癌診断検査の世界市場:医療機器のパイプライン評価

Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020

出版日: | 発行: GlobalData | ページ情報: 英文 56 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.72円
子宮頸癌診断検査の世界市場:医療機器のパイプライン評価
出版日: 2020年11月30日
発行: GlobalData
ページ情報: 英文 56 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の子宮頸癌診断検査の関連製品の市場における、主要なパイプライン製品とその治験の進行状況について調査すると共に、製品の機能・特性の比較分析 (治験の進行段階別) や、主要企業のプロファイルおよび代表的製品、昨今の市場動静 (業績報告・資本取引動向など) といった情報を取りまとめてお届けいたします。

第1章 目次

第2章 イントロダクション

  • 子宮頸癌診断検査の概要

第3章 治験中の製品

  • パイプライン製品:治験段階別
  • パイプライン製品:地域別
  • パイプライン製品:規制経路別
  • パイプライン製品:推定認証時期別
  • パイプライン製品:現在進行中の治験

第4章 治験中のパイプライン製品:企業別

  • 子宮頸癌診断検査の企業:治験段階別のパイプライン製品
  • 子宮頸癌診断検査:治験段階別のパイプライン製品

第5章 子宮頸癌診断検査市場:企業・製品の概要

  • Abbott Diagnostics
    • パイプライン製品および進行中の治験の概要
  • Aindra Systems Pvt. Ltd.
  • Alere Inc.
  • Arbor Vita Corporation
  • Becton, Dickinson and Company
  • BioAffinity Technologies, Inc.
  • BioMark Diagnostics Inc.
  • BioMark Technologies Inc.
  • Cancer Research Technology Limited
  • Cepheid
  • China Sky One Medical, Inc.
  • Cytosystems Ltd
  • Enzo Life Sciences, Inc.
  • Genisphere Inc.
  • Genomic Vision
  • GenomicTree, Inc.
  • Golden Valley Development, Inc.
  • GRANT Life Sciences, Inc.
  • Louisville Bioscience, Inc.
  • MDNA Life Sciences, Inc.
  • MDxHealth SA
  • Milagen, Inc.
  • NeoDiagnostix, Inc.
  • Newcastle University
  • Oncgnostics GmbH
  • ONCOVEDA Cancer Research Center
  • Orion Genomics LLC
  • Precision Biologics, Inc.
  • Preciva Incorporated
  • Roche Diagnostics International Ltd.
  • University of Manchester
  • US Biomarkers, Inc.
  • Vanderbilt University
  • Vigilant Biosciences, Inc.
  • XEPTAGEN SpA

第6章 子宮頸癌診断検査市場:昨今の動向 (全24件)

第7章 付録

図表一覧

図表

List of Tables

List of Tables

  • Table 1: Cervical Cancer - Pipeline Products by Stage of Development
  • Table 2: Cervical Cancer - Pipeline Products by Territory
  • Table 3: Cervical Cancer - Pipeline Products by Regulatory Path
  • Table 4: Cervical Cancer - Pipeline Products by E

List of Figures

List of Figures

  • Figure 1: Cervical Cancer - Pipeline Products by Stage of Development
  • Figure 2: Cervical Cancer - Pipeline Products by Territory
  • Figure 3: Cervical Cancer - Pipeline Products by Regulatory Path
  • Figure 4: Cervical Cancer - Pipeline Products
目次
Product Code: GDME1028EPD

GlobalData's Medical Devices sector report, "Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Cervical Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Cervical Cancer Diagnostic Tests are used for detection of cancer based on the detection and measurement of cancer-specific biomarker/antibody/antigen present in patient's sample.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Cervical Cancer Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Cervical Cancer Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Cervical Cancer Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Introduction

  • 2.1 Cervical Cancer Overview

3 Products under Development

  • 3.1 Cervical Cancer - Pipeline Products by Stage of Development
  • 3.2 Cervical Cancer - Pipeline Products by Territory
  • 3.3 Cervical Cancer - Pipeline Products by Regulatory Path
  • 3.4 Cervical Cancer - Pipeline Products by Estimated Approval Date

4 Cervical Cancer - Pipeline Products under Development by Companies

  • 4.1 Cervical Cancer Companies - Pipeline Products by Stage of Development
  • 4.2 Cervical Cancer - Pipeline Products by Stage of Development

5 Cervical Cancer Companies and Product Overview

6 Cervical Cancer- Recent Developments

  • 6.1 Oct 26, 2020: Cervical cancer study compares Dalrada Health VIA screening kits to pap smear, peer reviewed journal - The Gynecologist - publishes findings
  • 6.2 Jul 31, 2020: New Cervical Cancer Screening Guidelines from the American Cancer Society risk reversing decades of progress made against Cervical Cancer
  • 6.3 Jun 24, 2020: Cancer Genetics reports first quarter 2020 financial results and provides strategic business updates
  • 6.4 Mar 12, 2020: Roche gets FDA approval for cytology test to prevent cervical cancer
  • 6.5 Feb 26, 2020: MDxHealth reports financial year 2019 results and provides outlook for 2020
  • 6.6 Feb 06, 2020: BD announces results for 2020 first fiscal quarter; lowers fiscal 2020 guidance
  • 6.7 Jan 30, 2020: Quest Diagnostics reports record fourth quarter and full year 2019 revenues and earnings; provides guidance for full year 2020; increases dividend 5.7% to $0.56 per quarter
  • 6.8 Jan 30, 2020: Genomic Vision: Financial information for the fourth quarter of 2019
  • 6.9 Nov 20, 2019: Cancer Genetics reports third quarter 2019 financial results and provides strategic business update
  • 6.10 Nov 12, 2019: Cancer Research UK appoints new Executive Director of Fundraising and Marketing

7 Appendix

  • 7.1 Methodology
  • 7.2 About GlobalData
  • 7.3 Contact Us